In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

B-CONVINCED: Beta-blocker CONtinuation Versus INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode

Clinical Trial Update I

Heart Failure (HF)

Presenter | see Discussant report

Guillaume Jondeau, FESC (France)

Presentation webcast

Presentation slides

List of Authors:

Jondeau G, Neuder Y, Eicher JC, Jourdain P, Fauveau E, Galinier M, Jegou A, Bauer F, Trochu JN, Bouzamondo A, Tanguy ML, Lechat P, for the B-CONVINCED investigators

Whether or not beta-blocker therapy should be stopped during acutely decompensated heart failure (ADHF) is unsure.

In a randomised, controlled, open label, non inferiority trial, we compared beta-blockade continuation versus discontinuation during ADHF in patients with LVEF below 40% previously receiving stable beta-blocker therapy. 169 patients were included, among which 147 were evaluable. Mean age was 72±12 years, 65% were males.
After 3 days, 92.8% of patients pursuing beta-blockade improved for both dyspnea and general well being according to a physician blinded for therapy vs. 92.3% of patients stopping beta-blocker. This was the main end point and the upper limit for unilateral 95% CI for the difference (6.6%) is lower that the predefined upper limit (12.5%), indicating non-inferiority. Similar findings were obtained at 8 days and when evaluation was made by the patient. Plasma BNP at day 3, length of hospital stay, re-hospitalisation rate and death rate after 3 months were also similar. Beta-blocker therapy at 3 months was given to 90% of patients vs. 76% (p<0.05).

During ADHF, continuation of beta-blocker therapy is not associated with delayed or lesser improvement, but with a higher rate of chronic prescription of beta-blocker therapy after 3 months, the benefit of which is well established.

Discussant | see Presenter abstract

Presentation webcast





B-CONVINCED. Beta-blocker CONtinuation Versus INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode

Notes to editor

This congress report accompanies a presentation given at the ESC Congress 2009. Written by the author himself/herself, this report does not necessarily reflect the opinion of the European Society of Cardiology.

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.